| 000 | 01730 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516030418.0 | ||
| 264 | 0 | _c20110621 | |
| 008 | 201106s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/bjc.2011.81 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFan, F | |
| 245 | 0 | 0 |
_aChronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cApr 2011 |
||
| 300 |
_a1270-7 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCarcinoma _xpathology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xpathology |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aHCT116 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 700 | 1 | _aSamuel, S | |
| 700 | 1 | _aGaur, P | |
| 700 | 1 | _aLu, J | |
| 700 | 1 | _aDallas, N A | |
| 700 | 1 | _aXia, L | |
| 700 | 1 | _aBose, D | |
| 700 | 1 | _aRamachandran, V | |
| 700 | 1 | _aEllis, L M | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 104 _gno. 8 _gp. 1270-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bjc.2011.81 _zAvailable from publisher's website |
| 999 |
_c20678341 _d20678341 |
||